Table 2 Statin drugs, achieved lipid levels and CRP.
| Trial | Statin drug (mg/day) | Total‐C† mmol/l (% change) | LDL‐C† mmol/l (% change) | HDL‐C† mmol/l (% change) | TG† mmol/l (% change) | CRP mg/l (% change) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Int. | Mod. | Int. | Mod. | Int. | Mod. | Int. | Mod. | Int. | Mod. | Int. | Mod. | |
| A to Z,10 2004 | Simva 80 | Simva 20 | 3.6 (–25) | 4.1 (–15) | 1.7 (–41) | 2.1 (–27) | 1.1 (+13) | 1.1 (+13) | 1.3 (–22) | 1.4 (–14) | 1.5 (–93) | 1.8 (–91) |
| PROVE–IT TIMI 22,11 2004 | Atorva 80 | Prava 40 | NA | NA | 1.6 (–42) | 2.5 (–10) | 1.0 (+5) | 1.1 (+8) | 1.5 (–14) | 2.0 (+14) | 1.3 (–89) | 2.1 (–83) |
| IDEAL,12 2005 | Atorva 80 | Simva 20 | 4.0 (–22) | 4.6 (–10) | 2.1 (–34) | 2.7 (–14) | 1.3 (+9) | 1.3 (+11) | 1.3 (–21) | 1.5 (–7) | NA | NA |
| TNT,13 2005 | Atorva 80 | Atorva 10 | NA | NA | 2.0 (–49) | 2.6 (–34) | NA | NA | NA | NA | NA | NA |
| VASCULAR BASIS,14 2005* | Atorva 80 | Lova 5 | 3.8 (–35) | 5.1 (–14) | 2.0 (–46) | 3.1 (–21) | 1.2 (–4) | 1.2 (+12) | 1.2 (–38) | 1.8 (–9) | 1.7 (–37) | 2.5 (–7) |
| REVERSAL,15 2004 | Atorva 80 | Prava 40 | 3.9 (–34) | 4.9 (–18) | 2.1 (–46) | 2.9 (–25) | 1.1 (+3) | 1.2 (+6) | 1.7 (–20) | 1.9 (–7) | 1.8 (–36) | 2.9 (–5) |
Int, intensive statin therapy; Mod, moderate statin therapy; Simva, Simvastatin; Atorva, Atorvastatin; Prava, Pravastatin; Lova, Lovastatin; NA, not available.
*91% of patients in VASCULAR BASIS received a median dose of 5 mg/day of lovastatin, whereas 9% received only diet control.
†To convert Total‐C, LDL‐C, and HDL‐C from mmol/l to mg/dl, divide by 0.02586. To convert TG from mmol/l to mg/dl, divide by 0.01129.